About Zafrens
Zafrens is a company based in San Diego (United States) founded in 2021 by Yi Zhang. Zafrens has raised $29.16 million across 3 funding rounds from investors including imec.xpand, Prime Movers Lab and Kofa Healthcare. The company has 19 employees as of December 31, 2022. Zafrens offers products and services including Z-Screen, Active-seq, and Active-Drug-seq. Zafrens operates in a competitive market with competitors including 10X Genomics, Mission Bio, Singleron, Cellares and LUMICKS, among others.
- Headquarter San Diego, United States
- Employees 19 as on 31 Dec, 2022
- Founders Yi Zhang
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$29.16 M (USD)
in 3 rounds
-
Latest Funding Round
-
Investors
imec.xpand
& 9 more
-
Employee Count
19
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zafrens
Zafrens offers a comprehensive portfolio of products and services, including Z-Screen, Active-seq, and Active-Drug-seq.
High-throughput platform for cellular assays and sequencing.
Tool for mapping cell states to functional outcomes.
Platform for simultaneous molecular and phenotypic HTS.
People of Zafrens
Unlock access to complete
Funding Insights of Zafrens
Zafrens has successfully raised a total of $29.16M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
-
First Round
First Round
(13 Jan 2022)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Series A - Zafrens | Valuation |
investors |
|
| Dec, 2023 | Amount | Series A - Zafrens | Valuation | Prime Movers Lab | |
| Jan, 2022 | Amount | Series A - Zafrens | Valuation |
investors |
|
Investors in Zafrens
Zafrens has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include imec.xpand, Prime Movers Lab and Kofa Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is invested in early-stage semiconductor and nanotechnology firms.
|
Founded Year | Domain | Location | |
|
Kofa Healthcare is engaged in funding healthcare and biotech innovations.
|
Founded Year | Domain | Location | |
|
Global Brain is recognized as a venture capital firm supporting startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Zafrens
Financial Statements - Zafrens
Zafrens Comparisons
Competitors of Zafrens
Zafrens operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, Singleron, Cellares and LUMICKS, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| domain | founded_year | HQ Location |
Single-cell multi-omics platform is provided for genotypic and phenotypic analysis.
|
|
| domain | founded_year | HQ Location |
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis
|
|
| domain | founded_year | HQ Location |
Medical devices for cell-based therapy manufacturing are produced.
|
|
| domain | founded_year | HQ Location |
Optical tweezers instruments for single-molecule analysis are manufactured.
|
|
| domain | founded_year | HQ Location |
Single-cell imaging platform developed via magnetic levitation technology.
|
Frequently Asked Questions about Zafrens
Zafrens was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Zafrens is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Kandaswamy Vijayan is the current CEO of Zafrens.
Zafrens is a funded company, having raised a total of $29.16M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6.16M, raised on Jan 13, 2022.
As of Dec 31, 2022, the latest employee count at Zafrens is 19.
Provider of single-cell multi-omics analysis platform for researchers. The company specializes in building tools and generating insights at the interface of biology, chemistry, and engineering. It offers multi-omic assays and the study of mechanistic insights into the RNA regulatory layer.
Zafrens's top competitors include 10X Genomics, Mission Bio and Cellares.
Zafrens offers Z-Screen, Active-seq, and Active-Drug-seq.
Zafrens has 10 investors. Key investors include imec.xpand, Prime Movers Lab, Kofa Healthcare, Global Brain, and BlueYard Capital.